{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:34:07Z","timestamp":1790447647657,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102423","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:34:57Z","timestamp":1756362897000},"page":"102423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-2169","authenticated-orcid":false,"given":"Daniele","family":"Robesti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shesh N.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fallara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine G.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Malavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102423_bib0001","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102423_bib0002","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 Guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102423_bib0003","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring \u2014 A neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102423_bib0004","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12874-024-02313-3","article-title":"The impact of different censoring methods for analyzing survival using real-world data with linked mortality information: a simulation study","volume":"24","author":"Hsu","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clgc.2025.102423_bib0005","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/cncr.34255","article-title":"Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: the potential impact of informative censoring","volume":"128","author":"Martini","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2025.102423_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103801","article-title":"Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: a systematic review and meta-analysis","volume":"179","author":"Fallara","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2025.102423_bib0007","article-title":"Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation","volume":"12-2022","author":"Nocera","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2025.102423_bib0008","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euros.2023.03.009","article-title":"Contextualizing Olaparib and Abiraterone in the current treatment landscape for metastatic castration-resistant prostate cancer","volume":"52","author":"Fallara","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2025.102423_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102441","article-title":"Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis","volume":"110","author":"Fallara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2025.102423_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euros.2023.03.009","article-title":"Contextualizing Olaparib and Abiraterone in the current treatment landscape for metastatic castration-resistant prostate cancer","volume":"52","author":"Fallara","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2025.102423_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104815","article-title":"Trimodal treatment vs radical cystectomy for muscle-invasive bladder cancer: the neglected impact of informative censoring. A systematic review and meta-analysis","volume":"214","author":"Robesti","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2025.102423_bib0012","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2025.102423_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113942","article-title":"Equal censoring but still informative: when the reasons for censoring differ between treatment arms","volume":"201","author":"Olivier","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2025.102423_bib0014","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102423_bib0015","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102423_bib0016","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2025.102423_bib0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(23)00540-5","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","volume":"25","author":"Grande","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102423_bib0018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1470-2045(23)00539-9","article-title":"Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study","volume":"25","author":"Bamias","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102423_bib0019","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine\u2013Cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102423_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102423_bib0022","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102423_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114022","article-title":"Progression-free survival estimates are shaped by specific censoring rules: implications for PFS as an endpoint in cancer randomized trials","volume":"202","author":"Lesan","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2025.102423_bib0024","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.euf.2021.09.023","article-title":"Evidence-based urology: surrogate endpoints; for","volume":"7","author":"Martini","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2025.102423_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104321","article-title":"Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: a systematic review and network meta-analysis","volume":"196","author":"Monteiro","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2025.102423_bib0026","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:09:56Z","timestamp":1770671396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1558767325001235"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102423","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102423"}}